A Promising Genetic Target for Fighting Alzheimer's
Recent research at the University of Virginia suggests a specific gene, responsible for clearing brain debris, plays an essential role in Alzheimer's development. This discovery opens the way for new therapeutic strategies targeting this gene directly, aiming to treat or even prevent the devastating condition. The research team, led by John Lukens, PhD, examined the function of the CASS4 gene, previously identified in numerous studies as a risk factor for Alzheimer's. Their results demonstrated that this gene guides the activity of specialized immune cells in the brain, known as microglia. When the gene's correct function was disrupted, the consequences were severe: microglia could no longer react efficiently to harmful plaques forming in the brain, and their ability to confine and compact the toxins making up these plaques was significantly reduced. This allowed the plaques to grow faster and spread more aggressively.
Wellness insights
Social support networks of older adults before, during and after the COVID-19 pandemic
College Mental Health Crisis Shows Signs of Easing
Why Depression Subtypes Matter: 25 Years of Clinical Lessons
Choosing Adjunctive Therapy for Major Depressive Disorder: A Focus on Non-NegotiablesThese findings open new ground in understanding how this genetic risk factor contributes to Alzheimer's disease. Our work also suggests that defective CASS4 activity may serve as a biomarker for early detection of Alzheimer's, and therapeutic strategies that restore its function could offer a much-needed approach to treating this devastating brain disease. Dr. John Lukens, director of the Harrison Family Center for Translational Research on Neurodegenerative and Alzheimer's Diseases at UVA, stated.
Alzheimer's disease affects more than 6 million American citizens. It is a progressive condition that worsens over time, stealing memories until patients forget their own children. It is the sixth leading cause of death in the United States. Alzheimer's development is accompanied by the accumulation of sticky clusters of proteins inside the brain, known as beta-amyloid plaques, as well as twisted knots of tau proteins. Recent research has shown that the immune system—specifically microglia—may play a central role in this process. When functioning correctly, microglia form protective barriers around beta-amyloid plaques and compact them as much as possible to minimize the damage they can cause. However, Lukens' new research suggests that defective or ineffective variants of the gene can leave the brain inadequately defended. In laboratory mice, this compromised microglial function, caused beta-amyloid accumulation, damaged nerve cells called neurons, and sent the mice into cognitive decline.
Although CASS4 is an Alzheimer's risk gene, almost nothing was known about what this gene does and how it affects the brain during the disease. Our lab sought to address this major knowledge gap with this paper, said Addie Walsh, a UVA doctoral student in physiology and the paper's first author. These are important findings because they provide new understanding of how this under-studied AD risk gene functions in the brain and suggest that CASS4 may normally help microglia respond to amyloid pathology. The loss of CASS4 triggered a cascade of changes in gene activity that may contribute not only to Alzheimer's but also to other neurodegenerative diseases, as the researchers noted. Based on their results, scientists suspect that doctors may develop ways to target this gene or microglia in the brain to help slow or prevent the development of Alzheimer's.
We are now actively exploring the potential
We are now actively exploring the potential roles of CASS4 in multiple neurodegenerative disorders and developing new strategies to target it therapeutically, said Lukens from the Department of Neuroscience at the University of Virginia School of Medicine. Many in the field initially assumed CASS4 probably functioned in neurons to influence Alzheimer's. Our results change this paradigm, demonstrating that CASS4 acts predominantly through the immune system. This is particularly exciting because only in recent years have strategies targeting the immune system been considered for treating neurodegenerative diseases, and this remains an underexplored therapeutic pathway with enormous potential.
Lukens is part of the new Paul and Diane Manning Institute for Biotechnology at UVA. This institute was launched to accelerate the development of new drugs and treatments for complex diseases, based on UVA's cutting-edge biomedical research discoveries. Lukens is also a member of UVA's Brain Immune and Glial Center (BIG Center). In parallel, Walsh is preparing for the next step in her career. I will move to Boston at the end of the year to begin my postdoctoral research with the Neurodegeneration team at pharmaceutical company Novartis, she said. I look forward to continuing to study microglia in neurodegeneration.
The results were published by Lukens and colleagues in the Journal of Experimental Medicine. The research team included Adeline E. Walsh, Benjamin A. Davis, Joshua D. Samuels, William A. Mills III, Jessica M. Thanos, Alexis M. Johnson, Katelyn A. Moore, Michael A. Puchalski, Eric J. Steacy, Benjamin W. Wendell, Amélie Daugherty-Lopès, Adrian A. Shimpi, Ukpong B. Eyo, and Lukens. The scientists have no financial interests in the work. Davis is a fourth-year undergraduate in biology at UVA. I think undergraduate research develops a certain form of critical thinking that is difficult to cultivate in a classroom, he said. My experience with research has taught me to approach questions systematically and never to assume that I